ArticleLung cancer management2026

Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK.

Hannah Le et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.